Moderna shares plunge as leaked cancer vaccine data disappoints

In the latest trial, which enrolled more than 1100 patients, the mRNA vaccine was given to patients at high risk for recurrence after their melanoma was surgically removed. They…

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.afr.com)